Paul Lanz

Title: Paul Lanz - Innovator in Antibiotic Development

Introduction

Paul Lanz is a notable inventor based in Muttenz, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antibiotic compounds. With a total of 3 patents to his name, Lanz has demonstrated a commitment to advancing medical science through innovative research.

Latest Patents

Lanz's latest patents include groundbreaking work on cephalosporin derivatives. These patents present compounds of the formula ##STR1##, where R.sup.1 represents hydrogen or methyl, along with readily hydrolyzable esters and salts of these compounds and their hydrates. The acyl derivatives exhibit pharmacological activity as antibacterial agents. Another significant patent involves 6-acyl derivatives of aminopenicillanic acid. This patent discloses compounds represented by the formula ##EQU1##, wherein A is a substituted or unsubstituted heterocyclic radical, and T is a C.sub.2 -C.sub.5 alkyl, alkenyl, cyclopropylmethyl, cyclobutylmethyl, or cyclopentyl group. The process for their preparation and novel intermediates are also disclosed, highlighting their utility as effective antibiotics.

Career Highlights

Paul Lanz is currently associated with Hoffmann-La Roche Inc., a leading company in the pharmaceutical industry. His work at this esteemed organization has allowed him to focus on the development of innovative antibiotic solutions that address critical health challenges.

Collaborations

Throughout his career, Lanz has collaborated with esteemed colleagues such as Andre Furlenmeier and Peter Quitt. These collaborations have fostered a productive environment for research and innovation in antibiotic development.

Conclusion

Paul Lanz's contributions to antibiotic research and development underscore his role as a significant inventor in the pharmaceutical field. His innovative patents and collaborations continue to impact the medical community positively.